



**National Agency for Food & Drug Administration &
Control (NAFDAC)**

**Registration & Regulatory Affairs (R & R)
Directorate**

**SUMMARY OF PRODUCT CHARACTERISTICS
(SmPC) TEMPLATE**

ELATROCIN SUSPENSION (Erythromycin Stearate Oral Suspension 250 mg/5 ml)

Summary Product Characteristics (SPC)

1. NAME OF THE FINISHED PHARMACEUTICAL PRODUCT

ELATROCIN SUSPENSION (Erythromycin Stearate Oral Suspension 250 mg/5 ml)

1.1 Strength

Each 5 ml reconstitution suspension contains
 Erythromycin stearate BP
 Equivalent Erythromycin 250 mg
 Excipients Q.S.

1.2 Pharmaceutical form

Oral suspension

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Description: White and pink colour mixed powder, After reconstituted with water observed pink colour flavoured suspension

Sr. No.	Name of raw material	Specification	Label Claim	Qty. per 5 ml (mg)	Qty. per 100 ml (gm)
1.	Erythromycin stearate Equivalent Erythromycin	BP	250.00 mg/5ml	346.91 \cong 250.00	6.938
2.	Sucrose	BP	-	1392.10	27.842
3.	Sodium Propylparaben	BP	-	8.12	0.162
4.	Sodium Methylparaben	BP	-	5.04	0.101
5.	Saccharin Sodium	BP	-	4.84	0.097
6.	Anhydrous Citric Acid	BP	-	1.83	0.037
7.	Sodium Citrate	BP	-	6.58	0.132
8.	Ponceau 4 R colour	In-House	-	0.60	0.012
9.	Cherry flavour	In-House	-	17.00	0.340
10.	Croscarmellose Sodium	BP	-	16.98	0.340

* Removed after drying and does not present in the finished product

BP : British Pharmacopoeia

ELATROCIN SUSPENSION (Erythromycin Sterate Oral Suspension 250 mg/5 ml)

3. PHARMACEUTICAL FORM

Oral suspension

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

For the prophylaxis and treatment of infections caused by erythromycin-sensitive organisms.

Erythromycin is highly effective in the treatment of a great variety of clinical infections such as:

1. Upper Respiratory Tract infections: tonsillitis, peritonsillar abscess, pharyngitis, laryngitis, sinusitis, secondary infections in influenza and common colds
2. Lower Respiratory Tract infections: tracheitis, acute and chronic bronchitis, pneumonia (lobar pneumonia, bronchopneumonia, primary atypical pneumonia), bronchiectasis, Legionnaire's disease
3. Ear infection: otitis media and otitis externa, mastoiditis
4. Oral infections: gingivitis, Vincent's angina
5. Eye infections: blepharitis
6. Skin and soft tissue infections: boils and carbuncles, paronychia, abscesses, pustular acne, impetigo, cellulitis, erysipelas
7. Gastrointestinal infections: cholecystitis, staphylococcal enterocolitis
8. Prophylaxis: pre- and post- operative trauma, burns, rheumatic fever
9. Other infections: osteomyelitis, urethritis, gonorrhoea, syphilis, lymphogranuloma venereum, diphtheria, prostatitis, scarlet fever.

4.2 Posology and method of administration

For oral administration

Adults and children over 8 years: For mild to moderate infections 2g daily in divided doses. Up to 4g daily in severe infections.

Elderly: No special dosage recommendations.

Note: For younger children, infants and babies, Erythroped, erythromycin ethylsuccinate suspensions, are normally recommended. The recommended dose for children age 2-8 years, for mild to moderate infections, is 1 gram daily in divided doses. The recommended dose for infants and babies, for mild to moderate infections, is 500 mg daily in divided doses. For severe infections doses may be doubled

4.3 Method of administration

Route of administration is oral.

ELATROCIN SUSPENSION (Erythromycin Sterate Oral Suspension 250 mg/5 ml)

4.4 Contraindications

Known hypersensitivity to erythromycin.

Erythromycin is contraindicated in patients taking astemizole, terfenadine, cisapride or pimozone.

Erythromycin is contraindicated with ergotamine and dihydroergotamine.

4.5 Special warnings and precautions for use

Erythromycin is excreted principally by the liver, so caution should be exercised in administering the antibiotic to patients with impaired hepatic function or concomitantly receiving potentially hepatotoxic agents. Hepatic dysfunction including increased liver enzymes and/or cholestatic hepatitis, with or without jaundice, has been infrequently reported with erythromycin.

Pseudomembranous colitis has been reported with nearly all antibacterial agents, including macrolides, and may range in severity from mild to life-threatening. Clostridium difficile-associated diarrhoea (CDAD) has been reported with use of nearly all antibacterial agents including erythromycin, and may range in severity from mild diarrhoea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon, which may lead to overgrowth of *C. difficile*. CDAD must be considered in all patients who present with diarrhoea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.

There have been reports suggesting erythromycin does not reach the foetus in adequate concentrations to prevent congenital syphilis. Infants born to women treated during pregnancy with oral erythromycin for early syphilis should be treated with an appropriate penicillin regimen.

There have been reports that erythromycin may aggravate the weakness of patients with myasthenia gravis.

Erythromycin interferes with the fluorometric determination of urinary catecholamines. Rhabdomyolysis with or without renal impairment has been reported in seriously ill patients receiving erythromycin concomitantly with statins.

There have been reports of infantile hypertrophic pyloric stenosis (IHPS) occurring in infants following erythromycin therapy. In one cohort of 157 newborns who were given erythromycin for pertussis prophylaxis, seven neonates (5%) developed symptoms of non-bilious vomiting or irritability with feeding and were subsequently diagnosed as having IHPS requiring surgical pyloromyotomy. Since erythromycin may be used in the treatment of conditions in infants which are associated with significant mortality or morbidity (such as pertussis or chlamydia), the benefit of erythromycin therapy needs to be weighed against the potential risk of developing IHPS. Parents should be informed to contact their physician if vomiting or irritability with feeding occurs

ELATROCIN SUSPENSION (Erythromycin Sterate Oral Suspension 250 mg/5 ml)

4.6 Paediatric population

The recommended dose for infants and babies, for mild to moderate infections, is 500 mg daily in divided doses. For severe infections doses may be doubled.

4.7 Interaction with other medicinal products and other forms of interaction

Increases in serum concentrations of the following drugs metabolised by the cytochrome P450 system may occur : when administered concurrently with erythromycin: acenocoumarol, alfentanil, astemizole, bromocriptine, carbamazepine, cilostazol, cyclosporin, digoxin, dihydroergotamine, disopyramide, ergotamine, hexobarbitone, methylprednisolone, midazolam, omeprazole, phenytoin, quinidine, rifabutin, sildenafil, tacrolimus, terfenadine, domperidone, theophylline, triazolam, valproate, vinblastine, and antifungals e.g fluconazole, ketoconazole and itraconazole. Appropriate monitoring should be undertaken and dosage should be adjusted as necessary. Particular care should be taken with medications known to prolong the QTc interval of the electrocardiogram.

Drugs that induce CYP3A4 (such as rifampicin, phenytoin, carbamazepine, phenobarbital, St John's Wort) may induce the metabolism of erythromycin. This may lead to sub-therapeutic levels of erythromycin and a decreased effect. The induction decreases gradually during two weeks after discontinued treatment with CYP3A4 inducers. Erythromycin should not be used during and two weeks after treatment with CYP3A4 inducers.

HMG-CoA Reductase Inhibitors: erythromycin has been reported to increase concentrations of HMG-CoA reductase inhibitors (e.g. lovastatin and simvastatin). Rare reports of rhabdomyolysis have been reported in patients taking these drugs concomitantly.

Contraceptives: some antibiotics may in rare cases decrease the effect of contraceptive pills by interfering with the bacterial hydrolysis of steroid conjugates in the intestine and thereby reabsorption of unconjugated steroid. As a result of this plasma levels of active steroid may decrease.

Antihistamine H1 antagonists: care should be taken in the coadministration of erythromycin with H1 antagonists such as terfenadine, astemizole and mizolastine due to the alteration of their metabolism by erythromycin.

Erythromycin significantly alters the metabolism of terfenadine, astemizole and pimozide when taken concomitantly. Rare cases of serious, potentially fatal, cardiovascular events including cardiac arrest, torsade de pointes and other ventricular arrhythmias have been observed (see sections 4.3 and 4.8).

Anti-bacterial agents: an in vitro antagonism exists between erythromycin and the bactericidal beta-lactam antibiotics (e.g. penicillin, cephalosporin). Erythromycin antagonises the action of clindamycin, lincomycin and chloramphenicol. The same applies for streptomycin, tetracyclines and colistin.

Protease inhibitors: in concomitant administration of erythromycin and protease inhibitors, an inhibition of the decomposition of erythromycin has been observed.

ELATROCIN SUSPENSION (Erythromycin Sterate Oral Suspension 250 mg/5 ml)

Oral anticoagulants: there have been reports of increased anticoagulant effects when erythromycin and oral anticoagulants (e.g. warfarin) are used concomitantly.

Triazolobenzodiazepines (such as triazolam and alprazolam) and related benzodiazepines: erythromycin has been reported to decrease the clearance of triazolam, midazolam, and related benzodiazepines, and thus may increase the pharmacological effect of these benzodiazepines.

Post-marketing reports indicate that co-administration of erythromycin with ergotamine or dihydroergotamine has been associated with acute ergot toxicity characterised by vasospasm and ischaemia of the central nervous system, extremities and other tissues (see section 4.3).

Elevated cisapride levels have been reported in patients receiving erythromycin and cisapride concomitantly. This may result in QTc prolongation and cardiac arrhythmias including ventricular tachycardia, ventricular fibrillation and torsades de pointes. Similar effects have been observed with concomitant administration of pimozide and clarithromycin, another macrolide antibiotic.

Erythromycin use in patients who are receiving high doses of theophylline may be associated with an increase in serum theophylline levels and potential theophylline toxicity. In case of theophylline toxicity and/or elevated serum theophylline levels, the dose of theophylline should be reduced while the patient is receiving concomitant erythromycin therapy. There have been published reports suggesting when oral erythromycin is given concurrently with theophylline there is a significant decrease in erythromycin serum concentrations. This decrease could result in sub-therapeutic concentrations of erythromycin.

There have been post-marketing reports of colchicine toxicity with concomitant use of erythromycin and colchicine.

Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent verapamil, a calcium channel blocker.

Cimetidine may inhibit the metabolism of erythromycin which may lead to an increased plasma concentration.

Erythromycin has been reported to decrease the clearance of zopiclone and thus may increase the pharmacodynamic effects of this drug.

4.8 Additional information on special populations

None reported

4.9 Fertility, pregnancy and lactation

There are no adequate and well-controlled studies in pregnant women. However, observational studies in humans have reported cardiovascular malformations after exposure to medicinal products containing erythromycin during early pregnancy.

Erythromycin has been reported to cross the placental barrier in humans, but foetal plasma levels are generally low.

Erythromycin is excreted in breast milk, therefore, caution should be exercised when erythromycin is administered to a nursing mother.

ELATROCIN SUSPENSION (Erythromycin Sterate Oral Suspension 250 mg/5 ml)

4.10 Effects on ability to drive and use machines

None reported

4.11 Undesirable effects

The most frequent side effects of oral Erygloba-500 preparations are gastrointestinal and are dose-related. They include nausea, vomiting, abdominal pain, diarrhea and anorexia. Symptoms of hepatitis, hepatic dysfunction and/or abnormal liver function test results may occur.

Onset of pseudomembranous colitis symptoms may occur during or after antibacterial treatment.

Erygloba-500 has been associated with QT prolongation and ventricular arrhythmias, including ventricular tachycardia and torsades de pointes.

Allergic reactions ranging from urticaria to anaphylaxis have occurred. Skin reactions ranging from mild eruptions to erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis have been reported rarely.

There have been rare reports of pancreatitis and convulsions.

There have been isolated reports of reversible hearing loss occurring chiefly in patients with renal insufficiency and in patients receiving high doses of erythromycin.

4.12 Overdose

Symptoms: hearing loss, severe nausea, vomiting and diarrhoea.

Treatment: gastric lavage, general supportive measures.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

ATC code: J01FA01

Erythromycin exerts its antimicrobial action by binding to the 50S ribosomal sub-unit of susceptible microorganisms and suppresses protein synthesis. Erythromycin is usually active against most strains of the following organisms both in vitro and in clinical infections: Gram positive bacteria - *Listeria monocytogenes*, *Corynebacterium diphtheriae* (as an adjunct to antitoxin), *Staphylococci* spp, *Streptococci* spp (including *Enterococci*).

Gram negative bacteria - *Haemophilus influenzae*, *Neisseria meningitidis*, *Neisseria gonorrhoeae*, *Legionella pneumophila*, *Moraxella (Branhamella) catarrhalis*, *Bordetella pertussis*, *Campylobacter* spp.

Mycoplasma - *Mycoplasma pneumoniae*, *Ureaplasma urealyticum*.

Other organisms - *Treponema pallidum*, *Chlamydia* spp, *Clostridia* spp, L-forms, the agents causing trachoma and lymphogranuloma venereum.

Note: The majority of strains of *Haemophilus influenzae* are susceptible to the concentrations reached after ordinary doses.

ELATROCIN SUSPENSION (Erythromycin Sterate Oral Suspension 250 mg/5 ml)

5.2 Pharmacokinetic properties

Peak blood levels normally occur within one hour of dosing of erythromycin ethylsuccinate granules. The elimination half-life is approximately two hours. Doses may be administered two, three or four times a day.

Erythromycin ethylsuccinate is less susceptible than erythromycin to the adverse effect of gastric acid. It is absorbed from the small intestine. It is widely distributed throughout body tissues. Little metabolism occurs and only about 5% is excreted in the urine. It is excreted principally by the liver.

5.3 Preclinical safety data

No relevant data.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Sucrose	BP
Sodium Propylparaben	BP
Sodium Methylparaben	BP
Saccharin Sodium	BP
Anhydrous Citric Acid	BP
Sodium Citrate	BP
Ponceau 4 R colour	In-House
Cherry flavour	In-House
Croscarmellose Sodium	BP

6.2 Incompatibilities

Not applicable

6.3 Shelf life

24 months

6.4 Special precautions for storage

Store in a dark, dry place, Not exceeding 25 °C temp.

6.5 Nature and contents of container

100 ml bottle

ELATROCIN SUSPENSION (Erythromycin Sterate Oral Suspension 250 mg/5 ml)

6.6 Special precautions for disposal and other handling

Store in dark, dry place, not exceeding 25 °C temp.
KEEP OUT OF THE REACH AND SIGHT OF CHILDREN.

7. MARKETING AUTHORISATION HOLDER AND MANUFACTURING SITE ADDRESSES

MARKETING AUTHORISATION HOLDER

ELEONA PHARMACEUTICAL LTD.

6 Akinfenwa street,
Off oshogbo street orioke ogudu
Lagos, Nigeria

MANUFACTURED

SWISS PHARMA PVT. LTD.
3709, G.I.D.C. Phase IV, Vatva,
Ahmedabad –382445,
Gujarat, India
www.swisspharma.in

8. MARKETING AUTHORISATION NUMBER

Not Applicable

9. DATE OF FIRST REGISTRATION/RENEWAL OF THE REGISTRATION

Not Applicable

10. DATE OF REVISION OF THE TEXT

Mar 2020